Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
25,125
archived clinical trials in
Diabetes

The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes
A 26-weeks Randomised, Insulin Capped, Placebo-controlled, Double-blind, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated:  8/14/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Dallas, TX
The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes
A 26-weeks Randomised, Insulin Capped, Placebo-controlled, Double-blind, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated: 8/14/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Dallas, TX
Click here to add this to my saved trials
The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes
A 26-weeks Randomised, Insulin Capped, Placebo-controlled, Double-blind, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated:  8/14/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Murray, UT
The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes
A 26-weeks Randomised, Insulin Capped, Placebo-controlled, Double-blind, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated: 8/14/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Murray, UT
Click here to add this to my saved trials
The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes
A 26-weeks Randomised, Insulin Capped, Placebo-controlled, Double-blind, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated:  8/14/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Ogden, UT
The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes
A 26-weeks Randomised, Insulin Capped, Placebo-controlled, Double-blind, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated: 8/14/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Ogden, UT
Click here to add this to my saved trials
The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes
A 26-weeks Randomised, Insulin Capped, Placebo-controlled, Double-blind, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated:  8/14/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Bennington, VT
The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes
A 26-weeks Randomised, Insulin Capped, Placebo-controlled, Double-blind, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated: 8/14/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Bennington, VT
Click here to add this to my saved trials
The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes
A 26-weeks Randomised, Insulin Capped, Placebo-controlled, Double-blind, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated:  8/14/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Federal Way, WA
The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes
A 26-weeks Randomised, Insulin Capped, Placebo-controlled, Double-blind, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated: 8/14/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Federal Way, WA
Click here to add this to my saved trials
The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes
A 26-weeks Randomised, Insulin Capped, Placebo-controlled, Double-blind, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated:  8/14/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Renton, WA
The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes
A 26-weeks Randomised, Insulin Capped, Placebo-controlled, Double-blind, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated: 8/14/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Renton, WA
Click here to add this to my saved trials
The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes
A 26-weeks Randomised, Insulin Capped, Placebo-controlled, Double-blind, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated:  8/14/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Seattle, WA
The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes
A 26-weeks Randomised, Insulin Capped, Placebo-controlled, Double-blind, Parallel Group, Multinational, Multi-centre Trial
Status: Enrolling
Updated: 8/14/2014
Novo Nordisk Clinical Trial Call Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Efficacy of AutoloGel Therapy to Usual and Customary Care in Wagner gd 1 and 2 Diabetic Foot Ulcers.
A Multi-Center, Prospective, Clinical Trial Comparing the Efficacy of AutoloGel Therapy to Usual and Customary Care in Wagner 1 and 2 Diabetic Foot Ulcers
Status: Enrolling
Updated:  8/18/2014
Forest General Hospital
mi
from
Hattiesburg, MS
Efficacy of AutoloGel Therapy to Usual and Customary Care in Wagner gd 1 and 2 Diabetic Foot Ulcers.
A Multi-Center, Prospective, Clinical Trial Comparing the Efficacy of AutoloGel Therapy to Usual and Customary Care in Wagner 1 and 2 Diabetic Foot Ulcers
Status: Enrolling
Updated: 8/18/2014
Forest General Hospital
mi
from
Hattiesburg, MS
Click here to add this to my saved trials
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated:  8/25/2014
Clinical Research Facility
mi
from
Birmingham, AL
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated: 8/25/2014
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated:  8/25/2014
Clinical Research Facility
mi
from
La Jolla, CA
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated: 8/25/2014
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated:  8/25/2014
Clinical Research Facility
mi
from
Los Angeles, CA
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated: 8/25/2014
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated:  8/25/2014
Clinical Research Facility
mi
from
San Francisco, CA
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated: 8/25/2014
Clinical Research Facility
mi
from
San Francisco, CA
Click here to add this to my saved trials
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated:  8/25/2014
Clinical Research Facility
mi
from
Ft. Lauderdale, FL
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated: 8/25/2014
Clinical Research Facility
mi
from
Ft. Lauderdale, FL
Click here to add this to my saved trials
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated:  8/25/2014
Clinical Research Facility
mi
from
Jacksonville, FL
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated: 8/25/2014
Clinical Research Facility
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated:  8/25/2014
Clinical Research Facility
mi
from
Atlanta, GA
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated: 8/25/2014
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated:  8/25/2014
Clinical Research Facility
mi
from
Macon, GA
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated: 8/25/2014
Clinical Research Facility
mi
from
Macon, GA
Click here to add this to my saved trials
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated:  8/25/2014
Clinical Research Facility
mi
from
New Orleans, LA
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated: 8/25/2014
Clinical Research Facility
mi
from
New Orleans, LA
Click here to add this to my saved trials
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated:  8/25/2014
Clinical Research Facility
mi
from
New Orleans, LA
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated: 8/25/2014
Clinical Research Facility
mi
from
New Orleans, LA
Click here to add this to my saved trials
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated:  8/25/2014
Clinical Research Facility
mi
from
Baltimore, MD
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated: 8/25/2014
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated:  8/25/2014
Clinical Research Facility
mi
from
Detroit, MI
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated: 8/25/2014
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated:  8/25/2014
Clinical Research Facility
mi
from
Detroit, MI
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated: 8/25/2014
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated:  8/25/2014
Clinical Research Facility
mi
from
Petoskey, MI
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated: 8/25/2014
Clinical Research Facility
mi
from
Petoskey, MI
Click here to add this to my saved trials
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated:  8/25/2014
Clinical Research Facility
mi
from
Newark, NJ
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated: 8/25/2014
Clinical Research Facility
mi
from
Newark, NJ
Click here to add this to my saved trials
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated:  8/25/2014
Clinical Research Facility
mi
from
Hickory, NC
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated: 8/25/2014
Clinical Research Facility
mi
from
Hickory, NC
Click here to add this to my saved trials
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated:  8/25/2014
Clinical Research Facility
mi
from
Fairfield, OH
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated: 8/25/2014
Clinical Research Facility
mi
from
Fairfield, OH
Click here to add this to my saved trials
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated:  8/25/2014
Clinical Research Facility
mi
from
Philadelphia, PA
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status: Enrolling
Updated: 8/25/2014
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Determination of Safety,Tolerability,Pharmacokinetics,Food Effect& Pharmacodynamics of Single & Multiple Doses of P11187
A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety, Tolerability, Pharmacokinetics, Food Effect and Pharmacodynamics of Single and Multiple Ascending Doses of P11187
Status: Enrolling
Updated:  8/27/2014
Phase I clinic: MRA Clinical Research
mi
from
Miami, FL
Determination of Safety,Tolerability,Pharmacokinetics,Food Effect& Pharmacodynamics of Single & Multiple Doses of P11187
A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety, Tolerability, Pharmacokinetics, Food Effect and Pharmacodynamics of Single and Multiple Ascending Doses of P11187
Status: Enrolling
Updated: 8/27/2014
Phase I clinic: MRA Clinical Research
mi
from
Miami, FL
Click here to add this to my saved trials
The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006)
A Phase III Clinical Trial to Study the Safety and Efficacy of MK-1293 Compared to Lantus™ in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  8/28/2014
Clinical Research Facility
mi
from
Chula Vista, CA
The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006)
A Phase III Clinical Trial to Study the Safety and Efficacy of MK-1293 Compared to Lantus™ in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 8/28/2014
Clinical Research Facility
mi
from
Chula Vista, CA
Click here to add this to my saved trials
The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006)
A Phase III Clinical Trial to Study the Safety and Efficacy of MK-1293 Compared to Lantus™ in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  8/28/2014
Clinical Research Facility
mi
from
Los Angeles, CA
The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006)
A Phase III Clinical Trial to Study the Safety and Efficacy of MK-1293 Compared to Lantus™ in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 8/28/2014
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006)
A Phase III Clinical Trial to Study the Safety and Efficacy of MK-1293 Compared to Lantus™ in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  8/28/2014
Clinical Research Facility
mi
from
West Hills, CA
The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006)
A Phase III Clinical Trial to Study the Safety and Efficacy of MK-1293 Compared to Lantus™ in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 8/28/2014
Clinical Research Facility
mi
from
West Hills, CA
Click here to add this to my saved trials
The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006)
A Phase III Clinical Trial to Study the Safety and Efficacy of MK-1293 Compared to Lantus™ in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  8/28/2014
Clinical Research Facility
mi
from
Bradenton, FL
The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006)
A Phase III Clinical Trial to Study the Safety and Efficacy of MK-1293 Compared to Lantus™ in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 8/28/2014
Clinical Research Facility
mi
from
Bradenton, FL
Click here to add this to my saved trials
The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006)
A Phase III Clinical Trial to Study the Safety and Efficacy of MK-1293 Compared to Lantus™ in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  8/28/2014
Clinical Research Facility
mi
from
West Palm Beach, FL
The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006)
A Phase III Clinical Trial to Study the Safety and Efficacy of MK-1293 Compared to Lantus™ in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 8/28/2014
Clinical Research Facility
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006)
A Phase III Clinical Trial to Study the Safety and Efficacy of MK-1293 Compared to Lantus™ in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  8/28/2014
Clinical Research Facility
mi
from
Roswell, GA
The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006)
A Phase III Clinical Trial to Study the Safety and Efficacy of MK-1293 Compared to Lantus™ in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 8/28/2014
Clinical Research Facility
mi
from
Roswell, GA
Click here to add this to my saved trials
The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006)
A Phase III Clinical Trial to Study the Safety and Efficacy of MK-1293 Compared to Lantus™ in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  8/28/2014
Clinical Research Facility
mi
from
Omaha, NE
The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006)
A Phase III Clinical Trial to Study the Safety and Efficacy of MK-1293 Compared to Lantus™ in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 8/28/2014
Clinical Research Facility
mi
from
Omaha, NE
Click here to add this to my saved trials
The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006)
A Phase III Clinical Trial to Study the Safety and Efficacy of MK-1293 Compared to Lantus™ in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  8/28/2014
Clinical Research Facility
mi
from
Bristol, TN
The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006)
A Phase III Clinical Trial to Study the Safety and Efficacy of MK-1293 Compared to Lantus™ in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 8/28/2014
Clinical Research Facility
mi
from
Bristol, TN
Click here to add this to my saved trials
The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006)
A Phase III Clinical Trial to Study the Safety and Efficacy of MK-1293 Compared to Lantus™ in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  8/28/2014
Clinical Research Facility
mi
from
Dallas, TX
The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006)
A Phase III Clinical Trial to Study the Safety and Efficacy of MK-1293 Compared to Lantus™ in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 8/28/2014
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006)
A Phase III Clinical Trial to Study the Safety and Efficacy of MK-1293 Compared to Lantus™ in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  8/28/2014
Clinical Research Facility
mi
from
Dallas, TX
The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006)
A Phase III Clinical Trial to Study the Safety and Efficacy of MK-1293 Compared to Lantus™ in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 8/28/2014
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006)
A Phase III Clinical Trial to Study the Safety and Efficacy of MK-1293 Compared to Lantus™ in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  8/28/2014
Clinical Research Facility
mi
from
Houston, TX
The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006)
A Phase III Clinical Trial to Study the Safety and Efficacy of MK-1293 Compared to Lantus™ in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 8/28/2014
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Intensive Case Diabetes Management (ICDM) to Prevent Readmission
Intensive Case Diabetes Management to Prevent Readmission of Previously Identified High Risk Patients
Status: Enrolling
Updated:  8/29/2014
Barnes Jewish Hospital
mi
from
St. Louis, MO
Intensive Case Diabetes Management (ICDM) to Prevent Readmission
Intensive Case Diabetes Management to Prevent Readmission of Previously Identified High Risk Patients
Status: Enrolling
Updated: 8/29/2014
Barnes Jewish Hospital
mi
from
St. Louis, MO
Click here to add this to my saved trials
Glycemic Control Using Insulin Levemir Versus Insulin NPH for Diabetes in Pregnancy
Insulin Detemir Versus Insulin NPH: A Randomized Prospective Study Comparing Glycemic Control in Pregnant Women With Diabetes
Status: Enrolling
Updated:  9/12/2014
St Luke's - Roosevelt Hospital Center
mi
from
New York, NY
Glycemic Control Using Insulin Levemir Versus Insulin NPH for Diabetes in Pregnancy
Insulin Detemir Versus Insulin NPH: A Randomized Prospective Study Comparing Glycemic Control in Pregnant Women With Diabetes
Status: Enrolling
Updated: 9/12/2014
St Luke's - Roosevelt Hospital Center
mi
from
New York, NY
Click here to add this to my saved trials
A Mixed Methods Approach to the Development and Testing of the Measure of Drug Self-Management (MeDS)
A Mixed Methods Approach to the Development and Testing of the Measure of Drug Self-Management (MeDS), an Assessment for Use in Clinical Settings Among English and Spanish-speaking Patients With Hypertension and Diabetes.
Status: Enrolling
Updated:  9/12/2014
Ambulatory Care Center
mi
from
Chapel Hill, NC
A Mixed Methods Approach to the Development and Testing of the Measure of Drug Self-Management (MeDS)
A Mixed Methods Approach to the Development and Testing of the Measure of Drug Self-Management (MeDS), an Assessment for Use in Clinical Settings Among English and Spanish-speaking Patients With Hypertension and Diabetes.
Status: Enrolling
Updated: 9/12/2014
Ambulatory Care Center
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)
FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR
Status: Enrolling
Updated:  9/16/2014
So Calif. Permanente Medical Group
mi
from
San Diego, CA
FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)
FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR
Status: Enrolling
Updated: 9/16/2014
So Calif. Permanente Medical Group
mi
from
San Diego, CA
Click here to add this to my saved trials
FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)
FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR
Status: Enrolling
Updated:  9/16/2014
University of Miami
mi
from
Miami, FL
FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)
FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR
Status: Enrolling
Updated: 9/16/2014
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)
FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR
Status: Enrolling
Updated:  9/16/2014
Atlanta Diabetes Associates
mi
from
Atlanta, GA
FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)
FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR
Status: Enrolling
Updated: 9/16/2014
Atlanta Diabetes Associates
mi
from
Atlanta, GA
Click here to add this to my saved trials
FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)
FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR
Status: Enrolling
Updated:  9/16/2014
Joslin Diabetes Center
mi
from
Boston, MA
FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)
FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR
Status: Enrolling
Updated: 9/16/2014
Joslin Diabetes Center
mi
from
Boston, MA
Click here to add this to my saved trials
FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)
FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR
Status: Enrolling
Updated:  9/16/2014
International Diabetes Center
mi
from
Minneapolis, MN
FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)
FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR
Status: Enrolling
Updated: 9/16/2014
International Diabetes Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)
FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR
Status: Enrolling
Updated:  9/16/2014
Washington University
mi
from
St. Louis, MO
FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)
FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR
Status: Enrolling
Updated: 9/16/2014
Washington University
mi
from
St. Louis, MO
Click here to add this to my saved trials
FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)
FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR
Status: Enrolling
Updated:  9/16/2014
Kaledia Health of Western New York
mi
from
Buffalo, NY
FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)
FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR
Status: Enrolling
Updated: 9/16/2014
Kaledia Health of Western New York
mi
from
Buffalo, NY
Click here to add this to my saved trials
FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)
FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR
Status: Enrolling
Updated:  9/16/2014
Diabetes Care Center
mi
from
Durham, NC
FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)
FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR
Status: Enrolling
Updated: 9/16/2014
Diabetes Care Center
mi
from
Durham, NC
Click here to add this to my saved trials
FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)
FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR
Status: Enrolling
Updated:  9/16/2014
Oregon Health and Science University
mi
from
Portland, OR
FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)
FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR
Status: Enrolling
Updated: 9/16/2014
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials